Adequacy in Medical Technology

Genta Updates Progress of its Phase 3 Trial of Genasense(R) in Patients with Advanced Melanoma

... execute license and collaborative agreements, if any; -- the adequacy of the Company's capital resources and cash flow projections, the ... required by the transactional documents in our recent financing; -- the adequacy of the Company's patents and proprietary rights; -- the impact of ...

FDA Lifts Clinical Hold on Genta's Tesetaxel, a Leading Oral Taxane

... execute license and collaborative agreements, if any; -- the adequacy of the Company's capital resources and cash flow projections, the ... required by the transactional documents in our recent financing; -- the adequacy of the Company's patents and proprietary rights; -- the impact of ...

Genasense(R) Chemotherapy Program Yields High Response Rate in Patients with Stage 4 Melanoma

... execute license and collaborative agreements, if any; -- the adequacy of the Company's capital resources and cash flow projections, the ... bankruptcy if it is unsuccessful in obtaining such financing; -- the adequacy of the Company's patents and proprietary rights; -- the impact of ...

Long-Term Followup in Phase 3 CLL Trial Shows Genasense(R) is Associated with Significantly Increased Survival in All Responders

... execute license and collaborative agreements, if any; -- the adequacy of the Company's capital resources and cash flow projections, the ... bankruptcy if it is unsuccessful in obtaining such financing; -- the adequacy of the Company's patents and proprietary rights; -- the impact of ...

Genta Clinical Programs Featured in Multiple Abstracts at the Annual Meeting of the American Society of Clinical Oncology

... execute license and collaborative agreements, if any; -- the adequacy of the Company's capital resources and cash flow projections, and the ... financing to maintain the Company's planned operations; -- the adequacy of the Company's patents and proprietary rights; -- the impact of ...

Genta Receives Key Patent Related to Oral Gallium Compound G4544

... execute license and collaborative agreements, if any; -- the adequacy of the Company's capital resources and cash flow projections, and the ... financing to maintain the Company's planned operations; -- the adequacy of the Company's patents and proprietary rights; -- the impact of ...

Specialized Genasense(R) Clinical Trials Featured at AACR Meeting

... execute license and collaborative agreements, if any; -- the adequacy of the Company's capital resources and cash flow projections, and the ... financing to maintain the Company's planned operations; -- the adequacy of the Company's patents and proprietary rights; -- the impact of ...

DSMB Supports Continuation of Phase 3 AGENDA Trial of Genasense(R) in Advanced Melanoma

... execute license and collaborative agreements, if any; -- the adequacy of the Company's capital resources and cash flow projections, and ... financing to maintain the Company's planned operations; -- the adequacy of the Company's patents and proprietary rights; -- the impact of ...

FDA Indicates That Genasense(R) Approval in Chronic Lymphocytic Leukemia Will Require Additional Confirmatory Data

... execute license and collaborative agreements, if any; -- the adequacy of the Company's capital resources and cash flow projections, and the ... financing to maintain the Company's planned operations; -- the adequacy of the Company's patents and proprietary rights; -- the impact of ...

Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights

... execute license and collaborative agreements, if any; -- the adequacy of the Company's capital resources and cash flow projections, and the ... financing to maintain the Company's planned operations; -- the adequacy of the Company's patents and proprietary rights; -- the impact of ...

FDA Extends Review of Genasense(R) NDA Appeal in Chronic Lymphocytic Leukemia

... execute license and collaborative agreements, if any; -- the adequacy of the Company's capital resources and cash flow projections, and the ... financing to maintain the Company's planned operations; -- the adequacy of the Company's patents and proprietary rights; -- the impact of ...

FDA to Extend Review of Data Quality Submission for Genasense(R) in Melanoma

... execute license and collaborative agreements, if any; -- the adequacy of the Company's capital resources and cash flow projections, and the ... financing to maintain the Company's planned operations; -- the adequacy of the Company's patents and proprietary rights; -- the impact of ...

Genasense Plus Chemotherapy Is Associated With Prolonged Survival in Patients With Relapsed/Refractory CLL Who Achieve Complete Remission

... execute license and collaborative agreements, if any; -- the adequacy of the Company's capital resources and cash flow projections, and the ... financing to maintain the Company's planned operations; -- the adequacy of the Company's patents and proprietary rights; -- the impact of ...

Genta Clinical Programs Featured at American Society of Hematology Meeting

... execute license and collaborative agreements, if any; -- the adequacy of the Company's capital resources and cash flow projections, and the ... financing to maintain the Company's planned operations; -- the adequacy of the Company's patents and proprietary rights; -- the impact of ...

Genta Completes Initial Clinical Dosing of G4544, a New Oral Drug for Bone Diseases

... execute license and collaborative agreements, if any; -- the adequacy of the Company's capital resources and cash flow projections, and the ... financing to maintain the Company's planned operations; -- the adequacy of the Company's patents and proprietary rights; -- the impact of ...

Post-Hoc Data Show Daily Activity Participation, Independence and Sleep Quality Improved in Adults with Moderate to Severe Rheumatoid Arthritis After Treatment with ORENCIA(R) (Abatacept)

... was not significantly different. In the ATTAIN study, measurement of sleep adequacy was 9.0 in the ORENCIA group and 0.6 in the placebo group (p-value equals ... scales measuring awakened short of breath or with headache, snoring, adequacy or drowsiness were not significantly different in the AIM group. About ...

Genta Incorporated Announces Third Quarter 2007 Financial Results

... execute license and collaborative agreements, if any; -- the adequacy of the Company's capital resources and cash flow projections, and the ... financing to maintain the Company's planned operations; -- the adequacy of the Company's patents and proprietary rights; -- the impact of ...

Genasense(R) Data in Patients with Advanced Melanoma to be Featured at 4th International Melanoma Congress

... execute license and collaborative agreements, if any; -- the adequacy of the Company's capital resources and cash flow projections, and the ... financing to maintain the Company's planned operations; -- the adequacy of the Company's patents and proprietary rights; -- the impact of ...

Genasense(R) Can be Administered by Brief High-Dose IV Infusion

... execute license and collaborative agreements, if any; -- the adequacy of the Company's capital resources and cash flow projections, and the ... financing to maintain the Company's planned operations; -- the adequacy of the Company's patents and proprietary rights; -- the impact of ...

Authorization for AGENDA Phase 3 Trial of Genasense(R) in Advanced Melanoma Granted by French Regulatory Agency

... execute license and collaborative agreements, if any; -- the adequacy of the Company's capital resources and cash flow projections, and the ... financing to maintain the Company's planned operations; -- the adequacy of the Company's patents and proprietary rights; -- the impact of ...

Genta Initiates First Clinical Trial with New Oral Drug (G4544) to Treat Bone Disease

... execute license and collaborative agreements, if any; -- the adequacy of the Company's capital resources and cash flow projections, and the ... financing to maintain the Company's planned operations; -- the adequacy of the Company's patents and proprietary rights; -- the impact of ...

Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology

... execute license and collaborative agreements, if any; -- the adequacy of the Company's capital resources and cash flow projections, and the ... financing to maintain the Company's planned operations; -- the adequacy of the Company's patents and proprietary rights; -- the impact of ...

Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma

... execute license and collaborative agreements, if any; * the adequacy of the Company's capital resources and cash flow projections, and the ... financing to maintain the Company's planned operations; * the adequacy of the Company's patents and proprietary rights; * the impact of ...

Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights

... execute license and collaborative agreements, if any; -- the adequacy of the Company's capital resources and cash flow projections, and the ... financing to maintain the Company's planned operations; -- the adequacy of the Company's patents and proprietary rights; -- the impact of ...

Medivation Announces Positive New Efficacy Data From Phase 1-2 Trial of MDV3100 in Advanced Prostate Cancer Patients

... manufacturing of Medivation's product candidates, competition with Medivation's product candidates should they receive marketing approval, the adequacy of Medivation's financial resources, unanticipated expenditures or liabilities, intellectual property matters, and other risks detailed in ...

Food and Drug Administration Accepts Isolagen's Biologics License Application for Full Review

... BLA. Also, the acknowledgment of filing by the FDA does not mean that the FDA has issued a license, nor did the FDA represent any evaluation of the adequacy of the data submitted. About Isolagen, Inc. Isolagen(TM), Inc. (NYSE Amex: ILE ) is an aesthetic and therapeutic company committed to ...

Pfizer and Medivation Initiate Phase 3 Trial of Dimebon Added to Donepezil in Patients with Alzheimer's Disease

... manufacturing of Medivation's product candidates, competition with Medivation's product candidates should they receive marketing approval, the adequacy of Medivation's financial resources, unanticipated expenditures or liabilities, intellectual property matters, and other risks detailed in ...

AACR Data Highlights InNexus Preclinical Antibody Candidate

... To learn more about InNexus, please visit www.ixsbio.com . The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this news release. This news release may contain assumptions, estimates, and other forward-looking statements that involve inherent ...

Spectral presents data on the clinical utility of EAA(TM) at 13th Annual Critical Care for Endotoxemia conference in Japan

... differ materially from what is currently expected. The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this statement. ...

Oridion Announces Significant Medical Studies Presented at STA

... reports as providing a simple and clinically useful approach to assessing the interactions of heart rate, oxygen saturation, respiratory rate and adequacy of ventilation." Oridion is the global leader of innovative capnography monitoring solutions helping to improve patient safety and its ...

Phase III Trial Results Show Elitek(R) (rasburicase) Significantly Reduced Plasma Uric Acid Levels versus Allopurinol in Adults with Hematologic Cancers at Risk for Tumor Lysis Syndrome

... if not controlled. The primary objective of the multi-center, open-label, randomized, parallel group comparative study was to compare the adequacy of control of PUA concentration and the safety profile in three treatment arms. Among the three treatment arms, plasma uric acid response rate ...

Burcon announces GRAS status for Puratein(R) & Supertein(TM)

... Johann F. Tergesen President & Chief Operating Officer The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy of the content of the information contained herein. This press release contains forward-looking statements that involve risks and uncertainties. ...

Genaera Corporation Reports Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting

... antibody program may be delayed or may not be successful; the risk that Genaera may not obtain regulatory approval for its products, whether due to adequacy of the development program, the conduct of the clinical trials, changing regulatory requirements, different methods of evaluating and ...

Helix Receives Approval to Open Sites in Germany for its Ongoing Clinical Trial With Topical Interferon Alpha-2b in Patients With Ano-Genital Warts

... http://www.russopartnersllc.com The Toronto and Frankfurt Stock Exchanges have not reviewed and do not accept responsibility for the adequacy or accuracy of the content of this News Release. This News Release contains certain forward-looking statements and information regarding the ...

InNexus Lead Candidate DXL625 Outperforms Rituxan in Additional Animal Studies

... more about InNexus, please visit http://www.ixsbio.com . The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this news release. This news release may contain assumptions, estimates, and other forward-looking statements that involve inherent ...

Genaera Releases Phase 1 Data and New Preclinical Data on the CNS Function of Trodusquemine (MSI-1436) at CBI Obesity Summit

... antibody program may be delayed or may not be successful; the risk that Genaera may not obtain regulatory approval for its products, whether due to adequacy of the development program, the conduct of the clinical trials, changing regulatory requirements, different methods of evaluating and ...

Genaera Corporation Presents Data on Mechanism of Inhibition of PTP-1B for Trodusquemine (MSI-1436) at Federation of American Societies for Experimental Biology (FASEB) Meeting

... antibody program may be delayed or may not be successful; the risk that Genaera may not obtain regulatory approval for its products, whether due to adequacy of the development program, the conduct of the clinical trials, changing regulatory requirements, different methods of evaluating and ...

Genaera Corporation Presents Additional Promising Preclinical Type 2 Diabetes Data for Trodusquemine (MSI-1436) at American Diabetes Association

... antibody program may be delayed or may not be successful; the risk that Genaera may not obtain regulatory approval for its products, whether due to adequacy of the development program, the conduct of the clinical trials, changing regulatory requirements, different methods of evaluating and ...

Knowledge Based Reconstruction Demonstrates Accuracy in Obtaining Ventricular Volume and Function in Tetralogy of Fallot Patients, According to VentriPoint Diagnostics

... Ian Stone (619) 814-3510 ian.stone@russopartnersllc.com The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. ...

Three Dimensional Visualization of Right Ventricle Provides Important Information for Treatment of Patients with Tetralogy of Fallot, According to a Study in The American Journal of Cardiology

... (206) 283-0221, ext. 402 Facsimile: (206) 283-2309 The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. VentriPoint Media Contacts: Russo Partners LLC Ian Stone (619) 814-3510 ian.stone@russopartnersllc.com ...